Sunday 18 October 2026
Export AVIR’s income statement to Excel — free account
Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
4.32
0.21
−4.64%
Follow AVIR
Atea Pharmaceuticals, Inc. (AVIR) P/E ratio
Atea Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 236× (March 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 6.1× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2021 | 6.1× | (53.35%) |
| Sep 2021 | 13.1× | (22.33%) |
| Jun 2021 | 16.9× | (92.85%) |
| Mar 2021 | 236× | — |
| 1 more quarters | Free account |
Against its own ten years
Low 0.0×
High 236×
Ten-year median
0.0×
Current reading's percentile
70
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| FENC Adherex Technologies Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)